These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Intravenous clodronate in the treatment and retreatment of Paget's disease of bone.
    Author: Yates AJ, Percival RC, Gray RE, Atkins RM, Urwin GH, Hamdy NA, Preston CJ, Beneton MN, Russell RG, Kanis JA.
    Journal: Lancet; 1985 Jun 29; 1(8444):1474-7. PubMed ID: 2861411.
    Abstract:
    The effects of short courses (5 days) of intravenous clodronate 300 mg daily were studied in 31 patients with active Paget's disease of bone. The diphosphonate induced a striking reduction in biochemical indices of disease activity, which was sustained for at least 6 months after withdrawal of treatment. Apparent resistance to further treatment in patients previously treated for Paget's disease was an artefact due to incomplete relapse before retreatment. There was no significant difference in the degree of suppression of alkaline phosphatase activity between patients given intravenous clodronate and 45 patients given clodronate 1.6 g daily by mouth for 6 months. Short-term intravenous clodronate provides a useful alternative strategy for the treatment of patients with Paget's disease.
    [Abstract] [Full Text] [Related] [New Search]